Europe central precocious puberty (CPP) treatment market is projected to register a CAGR of 7.3% in the forecast period of 2020 to 2027. The new market report contains data for the historic year 2018, the base year of calculation is 2019 and the forecast period is 2020 to 2027.
Market Segmentation:
Europe Central Precocious Puberty (CPP) Treatment Market, By Type (Medication and Surgery), Month (1-Month, 3-Month, 6-Month and Others), Route of Administration (Parenteral, Implants, Oral and Others), Gender (Girls and Boys), End User (Hospitals, Specialty Clinics, Homecare and Others), Distribution Channel (Direct Tender, Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Others), Country (Germany, U.K., France, Italy, Spain, Switzerland, Netherlands, Russia, Turkey, Austria, Norway, Hungary, Lithuania, Ireland, Poland and Rest of Europe) Industry Trends and Forecast to 2027

Some of the major factors contributing to the growth of Europe central precocious puberty (CPP) treatment market are:

• Increasing cases of granulosa cell tumors
• Favorable government support for product approval

Market Players:

The key market players for Europe central precocious puberty (CPP) treatment market are listed below:

• Ipsen Pharma
• AbbVie Inc.
• Mylan N.V.
• Pfizer Inc.
• Takeda Pharmaceutical Company Limited
• GP Pharm
• Debiopharm
• AstraZeneca
• Sun Pharmaceutical Industries Ltd
• Endo International plc